The second bellwether trial in the Xarelto MDL ended with a defense verdict. The jury received the case this last Monday, and deliberated for a few hours before reaching their verdict. The plaintiff in the case suffered a stroke and alleged it was caused by Xarelto. Most of the 18,000 cases filed in the MDL allege bleeding events that led to hospitalization. It is unclear if the Plaintiff will appeal. This is the second trial in a row the plaintiffs have lost.
The plaintiff in the first bellwether trial, who also received a defense verdict from the jury, is asking for a new trial. That plaintiff alleged a gastrointestinal bleed for which he required hospitalization and blood transfusions. Although he is appealing on several grounds, one of his main contentions is that he was prevented from presenting the jury with evidence that a blood clotting test called Neoplastin PT should have been provided to patients in order to monitor any adverse reactions from Xarelto.
